240 related articles for article (PubMed ID: 22564130)
21. Current and emerging treatments for mild/moderate acute ambulatory pain.
Weaver AL
Am J Ther; 2008; 15 Suppl 10():S12-6. PubMed ID: 19127123
[TBL] [Abstract][Full Text] [Related]
22. Evolving guidelines in the use of topical nonsteroidal anti-inflammatory drugs in the treatment of osteoarthritis.
Balmaceda CM
BMC Musculoskelet Disord; 2014 Jan; 15():27. PubMed ID: 24444047
[TBL] [Abstract][Full Text] [Related]
23. Physicians' communication of risks from non-steroidal anti-inflammatory drugs and attitude towards providing adverse drug reaction information to patients.
Phueanpinit P; Pongwecharak J; Sumanont S; Krska J; Jarernsiripornkul N
J Eval Clin Pract; 2017 Dec; 23(6):1387-1394. PubMed ID: 28809071
[TBL] [Abstract][Full Text] [Related]
24. What is the most effective therapy for preventing NSAID-induced gastropathy?
Chandramouli J
J Pain Palliat Care Pharmacother; 2002; 16(2):23-36. PubMed ID: 14650458
[TBL] [Abstract][Full Text] [Related]
25. Review article: appropriate use of proton pump inhibitors with traditional nonsteroidal anti-inflammatory drugs and COX-2 selective inhibitors.
Kimmey MB; Lanas A
Aliment Pharmacol Ther; 2004 Feb; 19 Suppl 1():60-5. PubMed ID: 14725581
[TBL] [Abstract][Full Text] [Related]
26. The rate of prescribing gastrointestinal prophylaxis with either a proton pump inhibitor or an H2-receptor antagonist in Nova Scotia seniors starting nonsteroidal anti-inflammatory drug therapy.
Superceanu B; Veldhuyzen van Zanten S; Skedgel C; Shepherd M; Sketris I
Can J Gastroenterol; 2010 Aug; 24(8):481-8. PubMed ID: 20711527
[TBL] [Abstract][Full Text] [Related]
27. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents.
Chan FK; Abraham NS; Scheiman JM; Laine L;
Am J Gastroenterol; 2008 Nov; 103(11):2908-18. PubMed ID: 18853980
[TBL] [Abstract][Full Text] [Related]
28. Current approaches to prevent NSAID-induced gastropathy--COX selectivity and beyond.
Becker JC; Domschke W; Pohle T
Br J Clin Pharmacol; 2004 Dec; 58(6):587-600. PubMed ID: 15563357
[TBL] [Abstract][Full Text] [Related]
29. Preventing the gastrointestinal adverse effects of nonsteroidal anti-inflammatory drugs: from risk factor identification to risk factor intervention.
Bardou M; Barkun AN
Joint Bone Spine; 2010 Jan; 77(1):6-12. PubMed ID: 20022539
[TBL] [Abstract][Full Text] [Related]
30. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models.
Fries JF; Williams CA; Bloch DA; Michel BA
Am J Med; 1991 Sep; 91(3):213-22. PubMed ID: 1892140
[TBL] [Abstract][Full Text] [Related]
31. [NSAID GASTROPATHY IN PATIENTS WITH COMORBID DISEASES].
Morozova TE; Rykova SM; Chukina MA
Eksp Klin Gastroenterol; 2015; (6):64-70. PubMed ID: 26817107
[TBL] [Abstract][Full Text] [Related]
32. Prospective study of NSAIDs prescribing in Saudi Arabia: Cardiovascular and gastrointestinal risk in patients with diabetes mellitus
.
Mazhar F; Haider N; Sultana J; Akram S; Ahmed Y
Int J Clin Pharmacol Ther; 2018 Feb; 56(2):64-71. PubMed ID: 29208206
[TBL] [Abstract][Full Text] [Related]
33. NSAID-related gastrointestinal complications.
Soll AH; McCarthy D
Clin Cornerstone; 1999; 1(5):42-56. PubMed ID: 10682181
[TBL] [Abstract][Full Text] [Related]
34. Education-based approach to addressing non-evidence-based practice in preventing NSAID-associated gastrointestinal complications.
Lanas A; Esplugues JV; Zapardiel J; Sobreviela E
World J Gastroenterol; 2009 Dec; 15(47):5953-9. PubMed ID: 20014459
[TBL] [Abstract][Full Text] [Related]
35. From peptic ulcer disease to NSAID gastropathy. An evolving nosology.
Roth SH
Drugs Aging; 1995 May; 6(5):358-67. PubMed ID: 7647425
[TBL] [Abstract][Full Text] [Related]
36. Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis.
Latimer N; Lord J; Grant RL; O'Mahony R; Dickson J; Conaghan PG;
BMJ; 2009 Jul; 339():b2538. PubMed ID: 19602530
[TBL] [Abstract][Full Text] [Related]
37. Pharmacist intervention reduces gastropathy risk in patients using NSAIDs.
Ibañez-Cuevas V; Lopez-Briz E; Guardiola-Chorro MT;
Pharm World Sci; 2008 Dec; 30(6):947-54. PubMed ID: 18932013
[TBL] [Abstract][Full Text] [Related]
38. Nonsteroidal anti-inflammatory drug gastropathy at the new millennium: mechanisms and prevention.
Rich M; Scheiman JM
Semin Arthritis Rheum; 2000 Dec; 30(3):167-79. PubMed ID: 11124281
[TBL] [Abstract][Full Text] [Related]
39. Analysis of the costs of NSAID-associated gastropathy. Experience in a US health maintenance organisation.
Johnson RE; Hornbrook MC; Hooker RS; Woodson GT; Shneidman R
Pharmacoeconomics; 1997 Jul; 12(1):76-88. PubMed ID: 10169389
[TBL] [Abstract][Full Text] [Related]
40. Arthritis treatment in Hong Kong--cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents.
You JH; Lee KK; Chan TY; Lau WH; Chan FK
Aliment Pharmacol Ther; 2002 Dec; 16(12):2089-96. PubMed ID: 12452942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
